💬In plain words
What the trial is, and whether it could suit you
Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.
Four randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
\<Inclusion Criteria\>
1. Age ≥20 years
2. Acute ischemic stroke patients who underwent intraarterial thrombectomy for large vessel occlusion. (ICA, M1, M2, A1, P1, VA and BA)
3. Patients with successful recanalization after intraarterial thrombectomy (TICI 2b or TICI 3)
4. Patients with sustained systolic blood pressure (SBP) \<150 mm Hg on successive measurements obtained less than 10 minutes apart within 3 hours after reperfusion.
5. Patients with mean SBP \<150 mmHg within 2 hours after successful recanalization (two measurements ≥2 minutes apart).
\<Exclusion Criteria\>
1. Age \<20
2. Patients who failed recanalization of the intracranial artery after endovascular thrombectomy (modified TICI ≤ 2a).
3. Patients with systolic blood pressure ≥ 150 mmHg after successful recanalization.
4. Patients unable to receive antihypertensive medication post-thrombectomy or in whom the investigator believes aggressive blood pressure control could have adverse effects, such as increased risk of hemorrhage.
5. Patients who developed symptomatic intracranial hemorrhage before study enrollment, after successful recanalization.
6. Patients with contraindications to Phenylephrine.
7. Patients with contraindications to antihypertensive medications.
8. Patients with pre-stroke functional disability (modified Rankin Scale, mRS ≥3).
9. Patients with heart failure and reduced cardiac output, with an ejection fraction (EF) \<40%.
10. Patients with end-stage renal disease requiring renal replacement therapy, or chronic kidney disease stage 4 with an eGFR \<30 mL/min.
11. Patients currently taking monoamine oxidase (MAO) inhibitors.
12. Patients with persistent bradycardia with a heart rate \<45 bpm.
13. Pregnant patients.
14. Patients with severe medical or surgical comorbidities, including but not limited to: terminal cancer with life expectancy \<6 months, severe cardiac or aortic disease, severe hematologic disorders, advanced chronic heart failure, severe pneumonia, or sepsis.
15. Patients who do not consent to participate in the study.
16. Patients participating in another study that does not allow co-enrollment.
17. Patients whom the investigator deems unsuitable for study participation for any reason.
💊
What it tests
- BP lowering drugs (nicardipine, labetalol, urapidil)
- BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)
Department of Neurology, Yonsei University College of Medicine
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky